ERBB2 and breast carcinoma: The combination chemotherapy regimen of eribulin (ERI) and trastuzumab (TRA)-the ERI-TRA regimen-has been shown to be highly tolerable for patients with recurrent or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer.